Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide

about

TSH-Secreting Pituitary Adenoma: Current Management and Review.Thyrotropin-secreting pituitary adenomas: epidemiology, diagnosis, and management.

P2860

Q36684950-DFE66DE1-9FFC-457B-B1A5-358B87623537 Q38705219-9082609C-4662-405A-B622-04A902401261

P2860

Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide

Item

http://www.wikidata.org/entity/Q36681668

description

1991 nî lūn-bûn

@nan

1991年の論文

@ja

1991年論文

@yue

1991年論文

@zh-hant

1991年論文

@zh-hk

1991年論文

@zh-mo

1991年論文

@zh-tw

1991年论文

@wuu

1991年论文

@zh

1991年论文

@zh-cn

name

Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide

@ast

Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide

@en

type

Item

label

Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide

@ast

Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide

@en

prefLabel

Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide

@ast

Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide

@en

P1476

Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide

@en

P2093

Belchetz PE

http://www.w3.org/2001/XMLSchema#string

Lamb JT

http://www.w3.org/2001/XMLSchema#string

Nelson M

http://www.w3.org/2001/XMLSchema#string

Orme SM

http://www.w3.org/2001/XMLSchema#string

P2860

Thyrotropin-induced hyperthyroidism caused by selective pituitary resistance to thyroid hormone. A new syndrome of "inappropriate secretion of TSH".

NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.

Familial partial target organ resistance to thyroid hormones.

Neuroendocrine control of thyrotropin secretion.

Hyperthyroidism due to thyrotropin-secreting pituitary tumors. Diagnostic and therapeutic considerations.

Somatostatinoma syndrome. Biochemical, morphologic and clinical features.

Thyrotropin-induced hyperthyroidism: use of alpha and beta subunit levels to identify patients with pituitary tumors.

Hyperthyroidism and excessive thyrotropin secretion.

Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate.

Endocrine and morphologic studies of pituitary adenomas secondary to primary hypothyroidism.

P304

466-468

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/PGMJ.67.787.466

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

787

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

1991-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

21302652

http://www.w3.org/2001/XMLSchema#string

P698

1852668

http://www.w3.org/2001/XMLSchema#string

P932

2398861

http://www.w3.org/2001/XMLSchema#string

Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide

about

P2860

P2860

Shrinkage of thyrotrophin secreting pituitary adenoma treated with octreotide

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932